---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010154"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T20:37:07.203662+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix receives $20M milestone from Chiesi after FDA approval of ELFABRIO

## Summary
- $20M milestone triggered by FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) for Fabry disease; payable within 30 days.
- Proforma cash position including milestone is $51.6M as of May 18, 2023.
- Protalix has received $95M total in upfront and development cost payments from Chiesi under two agreements.
- Eligible for up to $1.0B in future regulatory and commercial milestones plus tiered royalties (15-40% US, 15-35% ex-US).
- CEO Dror Bashan states the payment strengthens financial position; partner Chiesi has global commercial expertise.

## SEC filing metadata
- accession: 0001558370-23-010154
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023010154/0001558370-23-010154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023010154/plx-20230518x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010154
- JSON: https://secwatch.observer/filing/0001558370-23-010154.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.